Compare DNA & LDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DNA | LDP |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.3M | 628.4M |
| IPO Year | N/A | N/A |
| Metric | DNA | LDP |
|---|---|---|
| Price | $9.39 | $21.33 |
| Analyst Decision | Strong Sell | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 979.7K | 102.5K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.91% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $180,606,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.00 | $16.16 |
| 52 Week High | $17.58 | $20.30 |
| Indicator | DNA | LDP |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 47.23 |
| Support Level | $8.56 | $21.26 |
| Resistance Level | $10.05 | $21.51 |
| Average True Range (ATR) | 0.55 | 0.18 |
| MACD | 0.27 | 0.02 |
| Stochastic Oscillator | 65.25 | 66.95 |
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.